Summary by Moomoo AI
TC BioPharm has entered into an At The Market Offering Agreement with H.C. Wainwright & Co. on December 16, 2024, enabling the company to sell American Depositary Shares (ADSs) with an aggregate sales price of up to $14 million. Each ADS represents 200 ordinary shares of the company. H.C. Wainwright will serve as the sales manager with a 3.0% commission on gross proceeds.The offering will be conducted through H.C. Wainwright's sales efforts on The Nasdaq Stock Market LLC or other existing trading markets, utilizing methods permitted by law and defined as "at the market offering" under Rule 415(a)(4). The ADSs are being offered pursuant to the company's effective shelf registration statement filed with the SEC on November 27, 2024.The agreement will terminate upon either the sale of shares reaching the $14 million aggregate offering price or termination by either party. The company maintains discretion over the timing and amount of any sales, with no obligation to sell any ADSs under the agreement.
